ArticleBMC cancer2025

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial.

Graham McIlroy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.